January 4, 2016
RegMed’s close: wait and watch 2016, it could be a year of living dangerously
December 31, 2015
RegMed’s close: the last day of trading expires
December 28, 2015
RegMed’s close: lower as traders cull any upside
December 21, 2015
Histogenics (HSGX) FDA has accepted its amendment regarding a NeoCart P3 clinical trial protocol
December 18, 2015
Downbeat trading expected. RegMed’s pre-open, beware the “witches broom”
December 15, 2015
RegMed’s close: my pattern analysis indicated the sector had to be UP
December 6, 2015
Bellicum Pharma (BLCM) BP-004 P1/2 followed by an add-back of BPX-501 donor T cells clinical trial data demonstrates no transplant-related mortality ...
December 6, 2015
bluebird bio (BLUE) Pre-Clinical data of its anti-BCMA oncology program in three oncology posters at ASH
December 2, 2015
Higher open expected. RegMed’s pre-open - confusing and mixed signals
December 1, 2015
Positive open expected. RegMed’s pre-open, “our” universe is a riddled with dysfunction
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.